CDER Compliance Director Recused From Most Duties Due To Husband's Promotion
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
The HHS general counsel determines that to prevent potential conflicts of interest, Cynthia Schnedar must no longer handle substantive issues for compliance actions and policy.
You may also be interested in...
CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues
Howard Sklamberg, deputy associate commissioner in FDA’s Office of Regulatory Affairs, will take over as director of the Center for Drug Evaluation and Research’s Compliance Office in January; acting compliance director Ilisa Bernstein will resume her role as deputy director.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: